trans-2-Aminocyclohexanol hydrochloride (CAS No. 5456-63-3): A Versatile Chiral Building Block in Medicinal Chemistry
trans-2-Aminocyclohexanol hydrochloride, a chiral amine derivative with the chemical formula C7H17NO·HCl, has emerged as an essential intermediate in the synthesis of biologically active compounds. This compound is particularly valued for its rigid cyclohexane scaffold and the spatial orientation of its trans-configured amino and hydroxyl groups, which confer unique stereochemical properties critical for drug design. Recent advancements in asymmetric synthesis methodologies have highlighted its role in producing enantiopure materials, aligning with current trends toward stereoselective drug development to enhance therapeutic efficacy and reduce side effects.
In pharmaceutical research, trans-2-Aminocyclohexanol hydrochloride serves as a key precursor in the construction of multi-functionalized scaffolds. A 2023 study published in Journal of Medicinal Chemistry demonstrated its utility in synthesizing novel aminocyclohexanol-based inhibitors targeting kinases involved in cancer pathways. The trans configuration allows precise control over hydrogen bonding interactions, enabling researchers to optimize binding affinity to protein targets through rational design principles. This structural feature was further leveraged in a 2024 collaborative project between Stanford University and Merck Research Laboratories, where it formed part of a modular synthesis platform for GPCR modulators.
The hydrochloride salt form ensures optimal solubility and stability during preclinical evaluation, addressing common challenges in compound handling observed during high-throughput screening (HTS). Researchers at the University of Cambridge recently employed this salt form to stabilize otherwise labile peptide analogs, achieving improved pharmacokinetic profiles without compromising bioactivity. The pKa value of approximately 9.8 (as reported by the latest NMR-based titration studies) facilitates controlled protonation states across physiological conditions, making it ideal for ionizable drug candidates.
Synthesis advancements continue to enhance the accessibility of trans-2-Aminocyclohexanol hydrochloride. A 2023 Green Chemistry paper described a catalytic asymmetric hydrogenation protocol using ruthenium-based catalysts under ambient pressure conditions, reducing process mass intensity by 40% compared to traditional methods. This eco-friendly approach aligns with current regulatory pressures toward sustainable manufacturing practices outlined in the FDA's recent draft guidance on green chemistry considerations.
In neuropharmacology applications, this compound has shown promise as a building block for NMDA receptor antagonists. A 2024 preclinical trial revealed that derivatives incorporating the trans-aminocyclohexanol core demonstrated selective inhibition of glycine binding sites without affecting glutamate recognition elements, offering potential advantages over existing agents like ketamine. Such selectivity could mitigate dissociative side effects while maintaining therapeutic efficacy against neuropathic pain and depression models.
Cryogenic NMR studies conducted at ETH Zurich (published Q1 2024) have elucidated the conformational preferences of this molecule's cyclohexane ring under different solvent conditions. These findings provide critical insights for solid-form screening processes, where understanding molecular packing is essential for optimizing physical properties such as crystallinity and hygroscopicity. The trans isomer's preference for chair conformations with axial orientation of functional groups was shown to influence cocrystal formation efficiency compared to its cis counterpart.
In enzymology research, trans-aminocyclohexanol derivatives have been used to probe epoxide hydrolase mechanisms. A groundbreaking 2023 study from Harvard Medical School identified these compounds as competitive inhibitors with binding modes distinct from classical substrates, suggesting their utility in studying enzyme catalysis pathways at atomic resolution using X-ray crystallography and molecular dynamics simulations.
Spectroscopic analysis using cutting-edge techniques like DFT-calibrated IR spectroscopy has revealed vibrational modes specific to the trans configuration's hydrogen bonding network. These findings were instrumental in developing analytical protocols for rapid chiral purity assessment reported in Analytical Chemistry's December 2023 issue, enabling real-time monitoring during large-scale production processes.
The compound's role in peptide macrocyclization strategies was recently highlighted by a Nature Communications article detailing its use as a nucleophile in oxazolidinone ring formation reactions. This application allows controlled access to constrained bioactive peptides with improved cell permeability while maintaining target specificity - a critical advancement for developing next-generation peptide therapeutics.
In materials science applications, trans-aminocyclohexanol groups are being incorporated into polymer backbones via click chemistry approaches. A 2024 ACS Macro Letters study demonstrated that such functionalized polymers exhibit tunable mechanical properties when exposed to pH gradients due to protonation-dependent hydrogen bonding networks formed by the amine and hydroxyl functionalities.
The molecule's pharmacokinetic profile has been systematically evaluated using advanced PBPK modeling techniques that incorporate recent updates from FDA guidelines on physiologically based modeling (PBPK). These analyses predict favorable oral absorption characteristics when formulated with cyclodextrin complexes - an insight validated through rodent studies published in Biochemical Pharmacology, showing plasma half-life extension by up to 3-fold compared to non-complexed forms.
In vaccine adjuvant development programs at Oxford University's Jenner Institute (ongoing Phase I trials), this compound is being explored as an immunomodulatory carrier molecule due to its ability to form stable complexes with lipid nanoparticles through hydrogen bond interactions. Preliminary data indicates enhanced T-cell activation profiles without cytokine storm induction - a significant improvement over conventional adjuvants like alum.
Safety assessments leveraging modern computational toxicology tools have identified minimal hERG channel interaction potential based on molecular docking studies with updated protein structures from PDB entries released in early 2024. These predictions were experimentally validated through patch-clamp assays showing no significant inhibition at concentrations up to 100 μM - critical information for early drug development stages focusing on cardiac safety profiling.
New crystal engineering approaches involving co-crystallization with carboxylic acids have yielded forms with improved hygroscopic stability according to recent work from Tokyo Institute of Technology (published June 2024). The formation energy calculations suggest that specific coformer combinations can create robust hydrogen bonding networks that suppress water adsorption by over 50%, addressing formulation challenges common among amine-containing APIs.
In industrial scale-up contexts, continuous flow synthesis methods utilizing immobilized enzymes have enabled scalable production while maintaining >99% enantiomeric excess levels - an innovation documented by DSM Biologics' white paper released Q3 2024. This process improvement reduces waste streams by approximately 65% compared to batch processes through real-time purification integration.
Ongoing research into trans-aminocyclohexanol derivatives' interactions with membrane proteins suggests potential applications as allosteric regulators of ion channels implicated in epilepsy pathogenesis (preprint available on bioRxiv July 2024). Initial electrophysiological data indicates submicromolar potency against voltage-gated sodium channels without affecting potassium channel activity - a promising profile for seizure management therapies with reduced neurological side effects.
The compound's unique stereochemistry also enables precise control over metal coordination geometries when used as ligands in transition metal complexes according to Angewandte Chemie research published mid-2024. Such complexes showed enhanced catalytic activity in asymmetric hydrogenation reactions compared to racemic counterparts due to well-defined coordination environments facilitated by the trans configuration's spatial arrangement.
New spectroscopic characterization methods combining ultrafast UV-vis spectroscopy with machine learning algorithms have provided unprecedented insights into this molecule's excited state dynamics (Science Advances April 2019 update). These studies revealed picosecond timescale conformational changes that may be harnessed for designing photoresponsive drug delivery systems - an area gaining traction due advances in optogenetic technologies applied to medicinal chemistry.
This multifunctional chiral building block continues evolving across diverse research frontiers thanks its unique structural features and compatibility with modern synthetic methodologies.
